Concepts (212)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neisseria meningitidis | 8 | 2023 | 36 | 2.940 |
Why?
|
| Meningococcal Infections | 5 | 2022 | 24 | 2.470 |
Why?
|
| Pneumococcal Infections | 18 | 2024 | 287 | 2.280 |
Why?
|
| Pneumococcal Vaccines | 14 | 2024 | 252 | 1.570 |
Why?
|
| Streptococcus pneumoniae | 17 | 2024 | 320 | 1.380 |
Why?
|
| von Willebrand Factor | 3 | 2021 | 21 | 1.280 |
Why?
|
| HIV Infections | 17 | 2024 | 4946 | 1.090 |
Why?
|
| South Africa | 37 | 2024 | 7312 | 1.040 |
Why?
|
| Meningitis, Pneumococcal | 3 | 2022 | 19 | 1.030 |
Why?
|
| Influenza, Human | 4 | 2022 | 360 | 1.030 |
Why?
|
| Meningococcal Vaccines | 3 | 2022 | 12 | 0.990 |
Why?
|
| Meningitis | 2 | 2022 | 23 | 0.980 |
Why?
|
| Humans | 47 | 2024 | 14077 | 0.970 |
Why?
|
| Amphotericin B | 2 | 2016 | 10 | 0.960 |
Why?
|
| Meningitis, Cryptococcal | 3 | 2023 | 16 | 0.950 |
Why?
|
| Communicable Diseases | 2 | 2022 | 61 | 0.940 |
Why?
|
| Meningitis, Meningococcal | 3 | 2022 | 17 | 0.940 |
Why?
|
| Meningitis, Bacterial | 2 | 2022 | 32 | 0.920 |
Why?
|
| Sepsis | 2 | 2022 | 101 | 0.910 |
Why?
|
| Serogroup | 11 | 2023 | 134 | 0.840 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 2 | 2021 | 7 | 0.820 |
Why?
|
| Perinatal Death | 1 | 2022 | 32 | 0.780 |
Why?
|
| AIDS-Related Opportunistic Infections | 4 | 2023 | 194 | 0.730 |
Why?
|
| Cryptococcosis | 3 | 2022 | 17 | 0.710 |
Why?
|
| Female | 27 | 2024 | 8751 | 0.690 |
Why?
|
| Coinfection | 3 | 2019 | 268 | 0.680 |
Why?
|
| Male | 25 | 2024 | 6489 | 0.680 |
Why?
|
| Child, Preschool | 19 | 2024 | 1675 | 0.680 |
Why?
|
| Antifungal Agents | 5 | 2023 | 40 | 0.670 |
Why?
|
| Infant | 21 | 2024 | 2145 | 0.660 |
Why?
|
| Plasminogen | 1 | 2018 | 1 | 0.640 |
Why?
|
| ADAMTS13 Protein | 1 | 2018 | 7 | 0.640 |
Why?
|
| Bacteriophages | 1 | 2018 | 4 | 0.610 |
Why?
|
| Adolescent | 16 | 2024 | 2858 | 0.610 |
Why?
|
| von Willebrand Diseases | 1 | 2018 | 8 | 0.610 |
Why?
|
| Infant, Newborn | 14 | 2024 | 1410 | 0.570 |
Why?
|
| Population Surveillance | 5 | 2021 | 325 | 0.560 |
Why?
|
| Child | 15 | 2024 | 2180 | 0.550 |
Why?
|
| Deoxycholic Acid | 1 | 2016 | 2 | 0.540 |
Why?
|
| Incidence | 11 | 2024 | 655 | 0.530 |
Why?
|
| Anti-Bacterial Agents | 6 | 2022 | 274 | 0.500 |
Why?
|
| Influenza Vaccines | 3 | 2021 | 132 | 0.500 |
Why?
|
| Vaccines, Conjugate | 6 | 2024 | 161 | 0.470 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2014 | 186 | 0.470 |
Why?
|
| Vaccination | 8 | 2023 | 347 | 0.450 |
Why?
|
| Adult | 17 | 2024 | 5664 | 0.440 |
Why?
|
| Hospital Mortality | 4 | 2023 | 94 | 0.440 |
Why?
|
| Risk Factors | 11 | 2024 | 1431 | 0.430 |
Why?
|
| Cryptococcus gattii | 1 | 2012 | 2 | 0.420 |
Why?
|
| Aged | 9 | 2024 | 1650 | 0.420 |
Why?
|
| Prevalence | 5 | 2021 | 1149 | 0.400 |
Why?
|
| Bacterial Infections | 2 | 2023 | 53 | 0.390 |
Why?
|
| Middle Aged | 11 | 2024 | 3425 | 0.390 |
Why?
|
| Young Adult | 10 | 2024 | 2357 | 0.370 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2019 | 184 | 0.330 |
Why?
|
| Hospitalization | 3 | 2024 | 392 | 0.330 |
Why?
|
| Carrier State | 2 | 2021 | 89 | 0.320 |
Why?
|
| Haemophilus influenzae | 3 | 2023 | 42 | 0.300 |
Why?
|
| Papio ursinus | 2 | 2023 | 3 | 0.270 |
Why?
|
| Spike Glycoprotein, Coronavirus | 2 | 2024 | 84 | 0.270 |
Why?
|
| Cross-Sectional Studies | 5 | 2022 | 1377 | 0.240 |
Why?
|
| Sentinel Surveillance | 2 | 2024 | 110 | 0.240 |
Why?
|
| Evolution, Molecular | 1 | 2024 | 60 | 0.230 |
Why?
|
| Bacteremia | 3 | 2015 | 79 | 0.230 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2021 | 507 | 0.230 |
Why?
|
| Hemostatics | 1 | 2023 | 17 | 0.220 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2018 | 124 | 0.220 |
Why?
|
| Fungemia | 1 | 2023 | 2 | 0.220 |
Why?
|
| Cryptococcus | 1 | 2023 | 10 | 0.210 |
Why?
|
| Respiratory Tract Infections | 2 | 2024 | 251 | 0.200 |
Why?
|
| Disease Progression | 1 | 2022 | 154 | 0.200 |
Why?
|
| Seasons | 1 | 2022 | 149 | 0.190 |
Why?
|
| Universities | 1 | 2021 | 34 | 0.180 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 171 | 0.180 |
Why?
|
| Cytokines | 1 | 2021 | 107 | 0.180 |
Why?
|
| Students | 1 | 2021 | 48 | 0.180 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2024 | 654 | 0.180 |
Why?
|
| Immune Evasion | 1 | 2021 | 31 | 0.180 |
Why?
|
| Neutralization Tests | 1 | 2021 | 106 | 0.180 |
Why?
|
| Biomarkers | 1 | 2021 | 322 | 0.170 |
Why?
|
| Premature Birth | 1 | 2021 | 76 | 0.170 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2021 | 137 | 0.170 |
Why?
|
| Hirudins | 1 | 1999 | 1 | 0.160 |
Why?
|
| Fibrinolytic Agents | 1 | 1999 | 7 | 0.160 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2021 | 176 | 0.160 |
Why?
|
| Streptococcus agalactiae | 2 | 2021 | 197 | 0.160 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2018 | 1 | 0.150 |
Why?
|
| Yeasts | 1 | 2018 | 3 | 0.150 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 235 | 0.150 |
Why?
|
| Blood Coagulation Tests | 1 | 2018 | 23 | 0.150 |
Why?
|
| Retrospective Studies | 2 | 2021 | 767 | 0.150 |
Why?
|
| Papio | 3 | 2023 | 28 | 0.140 |
Why?
|
| Genes, Bacterial | 1 | 2017 | 23 | 0.140 |
Why?
|
| Bacterial Capsules | 1 | 2017 | 33 | 0.140 |
Why?
|
| Genetic Variation | 2 | 2024 | 169 | 0.140 |
Why?
|
| Drug Combinations | 1 | 2016 | 41 | 0.130 |
Why?
|
| Animals | 4 | 2023 | 1063 | 0.130 |
Why?
|
| Treatment Outcome | 3 | 2017 | 867 | 0.130 |
Why?
|
| Epidemiological Monitoring | 1 | 2016 | 45 | 0.130 |
Why?
|
| Immunocompromised Host | 2 | 2012 | 33 | 0.130 |
Why?
|
| Statistics as Topic | 1 | 2015 | 31 | 0.130 |
Why?
|
| Prospective Studies | 2 | 2021 | 1131 | 0.120 |
Why?
|
| Ceftriaxone | 1 | 2014 | 13 | 0.120 |
Why?
|
| Mycoses | 1 | 2014 | 8 | 0.110 |
Why?
|
| Mortality | 3 | 2021 | 101 | 0.110 |
Why?
|
| Streptococcal Infections | 1 | 2016 | 179 | 0.110 |
Why?
|
| Age of Onset | 1 | 2012 | 32 | 0.100 |
Why?
|
| Length of Stay | 1 | 2012 | 43 | 0.100 |
Why?
|
| Sex Distribution | 1 | 2012 | 89 | 0.100 |
Why?
|
| Age Distribution | 1 | 2012 | 106 | 0.100 |
Why?
|
| Dysentery, Bacillary | 1 | 2012 | 3 | 0.100 |
Why?
|
| Tyrosine | 1 | 2012 | 2 | 0.100 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2012 | 4 | 0.100 |
Why?
|
| Anticoagulants | 1 | 2012 | 51 | 0.100 |
Why?
|
| Thrombosis | 1 | 2012 | 47 | 0.100 |
Why?
|
| Cryptococcus neoformans | 1 | 2010 | 1 | 0.090 |
Why?
|
| Age Factors | 3 | 2018 | 364 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2012 | 137 | 0.090 |
Why?
|
| Phylogeny | 2 | 2024 | 231 | 0.090 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 2 | 2024 | 42 | 0.090 |
Why?
|
| Pandemics | 2 | 2023 | 280 | 0.090 |
Why?
|
| Pregnancy | 3 | 2021 | 1815 | 0.080 |
Why?
|
| Case-Control Studies | 3 | 2017 | 464 | 0.080 |
Why?
|
| Ofloxacin | 1 | 2008 | 4 | 0.080 |
Why?
|
| Public Health Surveillance | 2 | 2021 | 52 | 0.080 |
Why?
|
| Levofloxacin | 1 | 2008 | 15 | 0.080 |
Why?
|
| Odds Ratio | 2 | 2017 | 132 | 0.070 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2008 | 210 | 0.060 |
Why?
|
| Antitubercular Agents | 1 | 2008 | 299 | 0.060 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 449 | 0.060 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2024 | 47 | 0.060 |
Why?
|
| Genome, Viral | 1 | 2024 | 64 | 0.060 |
Why?
|
| Thrombin | 1 | 2023 | 8 | 0.060 |
Why?
|
| ABO Blood-Group System | 1 | 2023 | 5 | 0.060 |
Why?
|
| Alleles | 2 | 2017 | 134 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 2 | 2017 | 180 | 0.060 |
Why?
|
| Antigens, Fungal | 1 | 2023 | 9 | 0.050 |
Why?
|
| Mutation | 1 | 2024 | 299 | 0.050 |
Why?
|
| Gram-Positive Bacteria | 1 | 2022 | 9 | 0.050 |
Why?
|
| Gram-Negative Bacteria | 1 | 2022 | 15 | 0.050 |
Why?
|
| Flucytosine | 1 | 2022 | 4 | 0.050 |
Why?
|
| Fluconazole | 1 | 2022 | 17 | 0.050 |
Why?
|
| Klebsiella pneumoniae | 1 | 2022 | 36 | 0.050 |
Why?
|
| Inflammation Mediators | 1 | 2021 | 22 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2024 | 939 | 0.050 |
Why?
|
| Public Health Practice | 1 | 2021 | 7 | 0.050 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2021 | 14 | 0.050 |
Why?
|
| Streptokinase | 1 | 2021 | 1 | 0.050 |
Why?
|
| Blood Donors | 1 | 2021 | 19 | 0.050 |
Why?
|
| Prognosis | 1 | 2021 | 197 | 0.050 |
Why?
|
| Pregnant Women | 1 | 2021 | 89 | 0.050 |
Why?
|
| Mice | 1 | 2021 | 134 | 0.050 |
Why?
|
| Immunization Programs | 1 | 2021 | 78 | 0.050 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2020 | 26 | 0.040 |
Why?
|
| Immunization | 1 | 2020 | 63 | 0.040 |
Why?
|
| Iodine Radioisotopes | 1 | 1999 | 3 | 0.040 |
Why?
|
| Partial Thromboplastin Time | 1 | 1999 | 13 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 1999 | 26 | 0.040 |
Why?
|
| Half-Life | 1 | 1999 | 21 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 1999 | 72 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 266 | 0.040 |
Why?
|
| Kidney | 1 | 1999 | 46 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2018 | 21 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2018 | 111 | 0.040 |
Why?
|
| Global Health | 1 | 2018 | 183 | 0.040 |
Why?
|
| Empyema | 1 | 2017 | 2 | 0.040 |
Why?
|
| Molecular Sequence Annotation | 1 | 2017 | 4 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2017 | 11 | 0.040 |
Why?
|
| Adhesins, Bacterial | 1 | 2017 | 12 | 0.040 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2017 | 5 | 0.040 |
Why?
|
| Virulence | 1 | 2017 | 25 | 0.040 |
Why?
|
| Genetic Loci | 1 | 2017 | 11 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2017 | 14 | 0.040 |
Why?
|
| Bronchiectasis | 1 | 2017 | 11 | 0.040 |
Why?
|
| Antigens, Bacterial | 1 | 2017 | 32 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2017 | 23 | 0.030 |
Why?
|
| Base Sequence | 1 | 2017 | 149 | 0.030 |
Why?
|
| Phenotype | 1 | 2017 | 144 | 0.030 |
Why?
|
| Live Birth | 1 | 2016 | 5 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 243 | 0.030 |
Why?
|
| Smoking | 1 | 2017 | 99 | 0.030 |
Why?
|
| Logistic Models | 1 | 2017 | 252 | 0.030 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2016 | 14 | 0.030 |
Why?
|
| Bacterial Proteins | 1 | 2017 | 117 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2016 | 37 | 0.030 |
Why?
|
| Streptococcal Vaccines | 1 | 2016 | 45 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 190 | 0.030 |
Why?
|
| Serotyping | 1 | 2015 | 63 | 0.030 |
Why?
|
| Demography | 1 | 2015 | 105 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2017 | 137 | 0.030 |
Why?
|
| Penicillin Resistance | 1 | 2014 | 17 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2015 | 131 | 0.030 |
Why?
|
| Seroepidemiologic Studies | 1 | 2015 | 104 | 0.030 |
Why?
|
| Penicillins | 1 | 2014 | 21 | 0.030 |
Why?
|
| Health Status | 1 | 2015 | 111 | 0.030 |
Why?
|
| Time Factors | 1 | 2015 | 503 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 405 | 0.030 |
Why?
|
| Shigella | 1 | 2012 | 2 | 0.030 |
Why?
|
| Primates | 1 | 2012 | 2 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2012 | 45 | 0.020 |
Why?
|
| Tuberculosis | 1 | 2017 | 530 | 0.020 |
Why?
|
| Ploidies | 1 | 2010 | 2 | 0.020 |
Why?
|
| DNA, Fungal | 1 | 2010 | 3 | 0.020 |
Why?
|
| Mycological Typing Techniques | 1 | 2010 | 2 | 0.020 |
Why?
|
| Genes, Mating Type, Fungal | 1 | 2010 | 2 | 0.020 |
Why?
|
| Multilocus Sequence Typing | 1 | 2010 | 19 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 263 | 0.020 |
Why?
|
| Genotype | 1 | 2010 | 430 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 38 | 0.020 |
Why?
|
| Cross Infection | 1 | 2008 | 49 | 0.020 |
Why?
|
| World Health Organization | 1 | 2008 | 134 | 0.020 |
Why?
|
| Rifampin | 1 | 2008 | 189 | 0.020 |
Why?
|